ArcticZymes Technologies - Earnings Release 2014

Interim results Q1 2014 for Biotec Pharmacon

Biotec Pharmacon ASA announces its results for the first quarter 2014.

FIRST QUARTER AND SUBSEQUENT EVENTS:

· Woulgan® Biogel has received CE-mark as an advanced medical device

for wound healing

Signed beta-glucan supply agreement with the aquaculture feed leader

Nutreco Skretting - marking a re-entry into the animal health market

Continued growth in end-user enzyme sales but revenue decline due to

natural fluctuations in rSAP sales to OEM customers

Strengthened equity and cash balance through share issue raising NOK 78

million at NOK 20 per share

OUTLOOK:

Commercial strategy for Woulgan® Biogel to be reviewed based on market

evaluation trial with international partner Smith & Nephew

Limited launch of Woulgan® Biogel in addition to the market evaluation

trial. Other beta-glucan sales set to increase in second half of the

year due to feed agreement with Nutreco Skretting

Gaining traction with several OEM partners within enzymes, and expecting

broader adoption of the enzyme portfolio going forward

Please find enclosed the complete interim report for Q1 2014.

For further information, please contact:

Svein W. F. Lien - CEO: +47 922 89 323

The company hosts a presentation of the interim results on Wednesday, 30

April at 08:30, at Thon Conference Vika Atrium, Munkedamsveien 45, Oslo.

It will be possible to follow the presentation as live video webcast

with log on at www.biotec.no

AI assistant